Posted: 4 November
VivaZome Therapeutics Pty Ltd (VivaZome) has announced that Ms Xenia Sango, Head of Regulatory and Clinical is speaking at Australia and New Zealand Society for Extracellular Vesicles (ANZSEV) in Gold Coast, Queensland 9 – 11 November 2022.
Ms Sango’s presentation “Regulatory Affairs Relating to EV-based Therapeutics” will focus on her personal experience in the biotechnology and pharmaceutical sectorss, including the registration of novel recombinant, plasma and vaccine products globally. She is a member of the International Society for Extracellular Vesicles (ISEV)’s Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics.
In addition, VivaZome’s CEO, Dr David Haylock, and Ms Sango will be part of an Expert Panel Discussion on “How to go Commercial” at the ANZSEV Conference and are also invited participants in a conference-associated Cytiva workshop on 10 November.
Dr Haylock and VivaZome Senior Scientist, Dr Smriti Krishna, are co-authors of the poster “Bioengineering exosomes to enhance brain targeting in a mouse traumatic brain injury model” by Dr Min Chen and colleagues from the University of Queensland.
ANZSEV is a membership organization that aims to promote the understanding, research and translation of Extracellular Vesicles (EVs) through an active national and international network and to create a common platform for members interested in EVs and nanoparticles. The ANZSEV Conference provides a world-class scientific program that focuses on advances in EV biology and technology, with broad impact and specific interest to delegates and Industry partners.
